Billions of dollars are pouring into new U.S. pharmaceutical manufacturing facilities, part of a broader push to bring critical drug production back onshore. And while the design and build phase has kicked off with ease – concrete is going up, equipment is being ordered – what’s missing is the same discipline applied to the talent who will actually run these plants. Pharma leaders must take a “construction crew” mindset and start treating workforce development in the same manner as they do critical infrastructure. A general contractor doesn’t wait until a building is framed to start thinking about electricians and plumbers, these trades are lined up months in advance. In practice, this means apprenticeships, university partnerships, technical training and regional pipelines need to be designed in parallel with the physical plant.
Over the past year, the US pharma industry has committed to one of the largest domestic manufacturing buildouts in its history. Roughly 14 to 15 major players in this space, including AbbVie, J&J, AstraZeneca, Pfizer, Merck, Roche, GSK, Eli Lilly – have active, or announced commitments for new build projects, totaling around $500 billion in new U.S. manufacturing and R&D investment. Eli Lilly alone is building four new plants in Alabama, Virginia, Texas and Pennsylvania, totaling a $27 Billion commitment. Abbvie is pursuing a $100 billion, decade long buildout.
This wave of investment didn’t happen in a vacuum; it’s the direct result of a policy mechanism. In April of this year, the Trump administration issued a proclamation imposing a 100% tariff on patented pharmaceutical products and their active ingredients, with exemptions only for companies that have both an approved onshoring plan and a signed pricing agreement with HHS. The catch – their new U.S. facilities must be completed by January 2029. Generics and biosimilars are exempt, so the pressure falls squarely on branded manufacturers, who are all now racing to meet this aggressive deadline.
The talent crunch
The facilities themselves span the country – Indiana, North Carolina, Texas, Virginia are just a few of the destinations. The recruiting effort to support these buildouts is already underway, and it will only intensify as facilities move from construction to commissioning over the next few years.
The credentialed talent pool required to run a modern pharmaceutical plant – GMP trained engineers, Delta V Automation specialists, sterile manufacturing operators – is narrow, and slow to expand. Unlike construction labor, which can scale up and demobilize as a project moves through phases, a manufacturing workforce has to be recruited, trained, certified and retained for the life of the facility. Most of the roles in pharma manufacturing require a multi-year commitment, not a temporary one.
This is exactly where the construction-crew mindset comes into play. Workforce development needs the same lead time and the same coordination, built as a parallel workstream from day one.
Apprenticeships
Apprenticeships aren’t a longstanding fixture of pharma manufacturing the way they have traditionally been in the trades. But there are several notable programs taking shape now, which will allow companies to build talent from the ground up. In North Carolina, Eli Lilly, FUJIFILM and CSL Seqirus recently launched a shared biomechatronics apprenticeship through the NC Life Sciences Apprenticeship Consortium. Similar programs have also launched in Pennsylvania supporting other tracks like chemistry lab technology and quality control. These programs will allow the workforce to be trained and ready for deployment when the plants become operable.
Educational partnerships driving regional pipelines
Apprenticeships alone won’t cover the talent gap – building a regional talent pipeline requires investment from the state and the companies that will benefit from it. In Virginia, AstraZeneca, Eli Lilly, and Merck signed a memorandum of understanding with the Commonwealth to launch the Virginia Center for Advanced Pharmaceutical Manufacturing, backed by around 120M in private investment and several educational institutions in the area. This center will produce thousands of trained professionals each year.
The same talent from adjacent regulated industries
Even with these strategies in place, pharma isn’t the only industry racing to build a workforce on a compressed timeline. The semiconductor industry is also experiencing a surge of domestic investment and they are competing for the same categories of technical talent in overlapping geographic areas. Micron is investing $200 billion across multiple U.S. fabrication plants, including new sites in Idaho and New York and an expansion in Virginia, a buildout expected to create 90,000 direct and indirect jobs. Texas Instruments is putting $60 billion into new fabrication plants in Texas and Utah, states where pharma manufacturers are also breaking ground.
This overlap doesn’t undercut the case for apprenticeships, educational partnerships, and regional pipelines. It strengthens it. But building those pipelines faster than competing industries also means rethinking who helps build them. Traditional staffing vendors and internal talent acquisition teams are built for steady-state hiring, not for a moment when pharma, semiconductor, and other regulated manufacturers are all recruiting from the same narrow bench at once. Closing the gap on this kind of timeline means bringing in specialized recruiting partners, ones who understand GMP environments and validation timelines and can source from adjacent regulated industries as readily as from pharma itself, and bringing them in during the design and construction phase. Companies that treat vendor diversification as part of their construction-crew planning, alongside apprenticeships and training pipelines, will have a real head start over those still relying on a single, familiar vendor to solve a problem this size.
Conclusion
The tariff exemption structure has created a talent crunch on a very compressed timeline. Hiring thousands of quality professionals to support these buildouts won’t be possible unless companies get creative. The ones that will succeed by 2029 will be the ones that built their workforce ecosystem, apprenticeships, educational partnerships, training programs, and the vendor networks behind them, just as early as their physical one.
Photo by Getty Images
Carolyn Durham brings over two decades of strategic leadership in workforce solutions, staffing, and consulting to her role as President of Planet Pharma, a leading life sciences staffing and consulting firm. In her current role, Carolyn focuses on driving operational efficiency and accelerating revenue growth across global markets, drawing on a proven track record of designing recruitment and delivery models that scale with client demand. Known for a consultative, partnership-driven approach, Carolyn works closely with clients to understand their goals, anticipate challenges, and deliver talent solutions that perform.
This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.
